Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.51 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471555 | 1.00 | CHRNB2 (0.51) | CHRNB2CHRNA4ORAI1MAPTRAB9A | |
| SCHEMBL14819179 | 0.82 | CYP19A1 (0.50) | CHRNB2CHRNA3CHRNB1CHRNB4 | |
| SCHEMBL15434709 | 0.81 | CHRNB2 (0.60) | CHRNB2CHRNA4ORAI1MAPTRAB9A | |
| SCHEMBL15677926 | 0.81 | CYP19A1 (0.60) | RAB9A | |
| SCHEMBL29539805 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL6364694 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL28205615 | 0.78 | CCNC (0.57) | CHRNB2CHRNA4ORAI1MAPTRAB9A | |
| SCHEMBL14351335 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4ORAI1MAPTRAB9A | |
| SCHEMBL5186748 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| Formic Acid SCHEMBL27578102 | 0.77 | CCNC (0.60) | CHRNB2CHRNA4MAPTRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3953341-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI Industries Ltd. (IN) | 2022-02-16 | — | — | EP | claimed |
| WO-2020208511-A1 | NOVEL OXADIAZOLE COMPOUNDS FOR CONTROLLING OR PREVENTING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LIMITED (IN) | 2020-10-15 | — | — | WO | claimed |
| WO-2023083295-A1 | ESTER DERIVATIVES OF N4-HYDROXYCYTIDINE AND USE THEREOF | SUZHOU SPRING-SEA BIO-PHARMACEUTICALS CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| EP-2523951-B1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8884030-B2 | Inhibitors of Flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-20130323203-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
| US-4155908-A | PSORIASIS, ANTICOAGULANTS | MERCK & CO., INC. (US) | 1979-05-22 | — | — | US | disclosed |
| US-4128564-A | 9-Thia- and oxothia- and 9-dioxothia-11,12-seco-prostaglandins | MERCK & CO., INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4102888-A | VASODILATORS, ANTITHROMBITIC | MERCK & CO., INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4085125-A | 9-Thia-, 9-oxothia-, and 9-dioxothia-11,12-seco-prostaglandins and processes | MERCK & CO., INC. (US) | 1978-04-18 | — | — | US | disclosed |
| US-4066675-A | PSORIASIS, THROMBOSIS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
| US-4059587-A | 8-AZA-9-OXO-11-THIA-PROSTANOIC ACID DERIVATIVES; VASODILATORS, ANTICLOTTING, REGULATORS OF IMMUNE RESPONSE | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4022794-A | VASODILATION | MERCK & CO., INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-4018802-A | SKIN DISEASES, GROWTH HORMONE STIMULANTS, THROMBUS PREVENTION, IMMUNOLOGY | MERCK & CO., INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | CHRNB2 4880/4885CHRNA4 4852/4885ORAI1 4873/4885 |
| US-20130323203-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | CHRNB2 4880/4885CHRNA4 4852/4885ORAI1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.